Background: Apelin receptor (APJ) is a G protein-coupled receptor (GPCR) activated by the endogenous peptide apelin. The apelin-APJ system has emerged as an important regulator of cardiovascular homeostasis. Recently, a potent benzimidazole-derived apelin peptidomimetic, CMF-019, was patented but without a comprehensive description of its synthesis and a complete spectroscopic characterization of the intermediates.
INTRODUCTION
APJ was identified in 1993; [1] it displays the classic structure associated with GPCRs [1] . Apelin, the endogenous peptidic agonist of APJ, was discovered in 1998 by K. Tatemoto et al. [2] . The expression pattern of apelin correlates with the localization of the receptor in many human tissues [3] . On the other hand, apelin is also expressed in cells such as adipocytes, which lack the APJ receptor, and it has been detected in plasma at "hormone"-like levels [3] . These data support the hypothesis that apelin might act as a humoral regulator of numerous body functions including cardiovascular homeostasis [4] . A number of mechanisms beneficial to the cardiovascular system, which might be modulated by APJ, have been proposed: positive inotropy, angiogenesis, CMF-019 exhibited impressive biological effects on the cardiovascular system via activation of APJ [11] . The availability of active peptidomimetic APJ-agonists such as CMF-019 could be helpful for elucidating vital physiological processes associated with an apelinergic signalling system. Currently, employment of APJ agonists as positive modulators of the cardiovascular system is under intense study and it has begun to attract the increasing attention of the scientific community. However, the earlier reported syntheses of CMF-019 and related compounds lack a detailed description of the experimental procedures and a spectroscopic characterization of the intermediates [10, 11] . Here, we unveil all the relevant details of the experimentally simplified and improved synthesis of CMF-019 (potassium salt), which largely follows the route briefly described by Read et al. [11] . We believe that the availability of reliable and reasonably yielding CMF-019 synthesis can be helpful towards clarifying the role of the apelin-APJ system in cardiovascular homeostasis and other vital physiological processes.
RESULTS AND DISCUSSION
The expedient synthesis of CMF-019 is shown in Scheme 1. In the first step, esterification of commercially available acid 1 with methanol and a catalytic amount of concentrated H 2 SO 4 , following a slightly modified reported procedure, [12] provided crude NMR-pure ester 2 at 91% yield. Treatment of crude 2 with 3-aminopentane in the presence of K 2 CO 3 in dry THF resulted in the efficient nucleophilic aromatic substitution of fluorine, affording aromatic secondary amine 3 (92%), which was found to be NMR-pure in a crude state. In our hands, the original procedure using DMF as a solvent [10] afforded a more complex reaction mixture that necessitated the tedious isolation of 3 [<80% yield after sequential flash chromatography (FC)]. According to the original procedure, the next high-yielding reduction of the nitro group in 3 to afford N-monosubstituted ortho-phenylenediamine 4 required 4 h of catalytic hydrogenation at 15 bar hydrogen pressure [10]. Since we are limited in high-pressure hydrogenation equipment, we successfully converted the crude nitroaniline 3 into phenylenediamine 4 (85% after FC purification) after 16 h of hydrogenation over 10% Pd/C catalyst (1.4 mol-% Pd loading) in ethanol under 5 bar hydrogen pressure in a regular Parr machine. Under these experimental conditions, a shortening of hydrogenation time to 4 h repeatedly led to the incomplete reduction and inferior yields of the intermediate 4 (60-64%). Nevertheless, a 4time elongation of the hydrogenation time successfully compensated for a 3-time lowering of the hydrogen pressure.
In the original approach, preparation of benzimidazole 7 relied on the acylation of 4 with 2-thiopheneacetyl chloride, followed by cyclization of the resulting amide in acetic acid at 140 o C under microwave irradiation [10, 11] . However, all attempts to accomplish such cyclization using a domestic microwave oven that was available in our lab were largely unsuccessful (<10% yield of 7 in the cyclization step). Perhaps the reported procedure [10, 11] could be reproduced by using scientific microwave reactors only [13] . Since our lab, like many other synthetic and medicinal chemistry laboratories, especially in developing countries, still lacks such an attractive, but rather expensive dedicated equipment, the microwave reactor-dependent step was replaced by a regular organic reaction. The direct cyclization of N-substituted ortho-phenylenediamine 4 with methyl 2-thiophenacetimidate hydrochloride 6 [14] was adopted. Indeed, iminoester salts are widely applied as one-carbon electrophiles and are generally more active than are carboxylic acids, in cyclizations with N-unsubstituted ortho-phenylenediamines affording Nunsubstituted benzimidazoles [15] . However, the set of nonpatented examples describing the condensation of imidate salts with N-substituted ortho-phenylenediamines to afford the corresponding N-substituted benzimidazoles is minimal, varying considerably in both synthetic viabilities and in the reaction conditions [16] . In the current study, imidate hydrochloride 6 was synthesized at 87% yield, according to a further development of a "modified Pinner method" [17] from commercially available 2-thiophene acetonitrile (5), methanol, and acetyl chloride in dry ether at 0 o C. The hydrolytically labile crystalline imidate salt 6 was precipitated directly from the reaction mixture, which significantly simplified its isolation. Subsequent reflux of N-alkyl-substituted orthophenylenediamine 4 and imidate hydrochloride 6 in dry methanol for 8 h led to the condensation of the reactants, affording the desired 5-carbmethoxybenzimidazole 7 (57%). Although the overall yields of benzimidazole 7 from 4 in the previously reported [10, 11] and in our approach are comparable, the reported herein "microwave-free" method could be more practical for many scientific teams dealing with synthesis.
From a mechanistic viewpoint, condensation of imidate salt 6 with ortho-phenylenediamine 4, producing benzimidazole 7, consists of two single steps: (i) slow intermolecular aminolysis of 6 by 4 and replacing the alkoxy-group by a more nucleophilic ArNH 2 -group and the formation of an unstable N-(2-alkylaminophenyl)amidinium-type intermediate; [18] and (ii) the subsequent rapid intramolecular aminolysis of the positively charged amidinium system by the neighbouring alkylarylamino-group, resulting in benzimidazole 7 ring closure [19] .
Basic hydrolysis of methyl ester 7, followed by acidification, afforded the free acid 8 in good yield [10] . The chiralamino ester residue was attached to the free carboxylic group of 8 by HOBt, and EDC induced condensation with commercially available enantiopure methyl (S)-3-amino-5methyl hexanoate [20] in dry DMF. A pure direct precursor, 9, was isolated at 58% yield after FC on a softly basic Florisil absorbent. In contrast, FC on a slightly acidic silica gel led to considerable decomposition of product 9. This observation supports the conclusion that low yields ofamidoacid CMF-019 (ca. 20%), obtained by the previously described condensation of 8 with (S)-3-amino-5-methylhexanoic acid, [10, 11] could have resulted from the inherent lability of the acidic form of CMF-019 rather than from insufficiency of the condensation process itself.
In the final step of the synthesis, deprotection of methyl ester 9 by directly converting to the potassium salt of CMF-019 (10) was accomplished. Formation of salt 10 probably improves the stability of CMF-019. Furthermore, the salt from 10 is critical for the compound's solubility in water and for its administration either to cells growing in medium or to animals [11] . Initially, we attempted to convert ester 9 to the potassium salt of CMF-019 (10) using purified potassium trimethylsilanolate, which is widely recognized as a superior reagent for conversion of methyl esters to potassium salts of the corresponding carboxylic acids [21] . However, our continuous experiments with Me 3 SiOK in dry THF or ether gave insufficient yields of 10 (20-30%). To our delight, ester 9 simply treated with KOH in THF/water, followed by reverse-phase HPLC-purification, afforded the desired product, CMF-019 (potassium salt) (10) (57% yield), as a hydroscopic colorless solid. In summary, the procedures reported here expedite the synthesis of CMF-019 (potassium salt) (10) to a total of 12% yield following seven linear steps.
MATERIALS AND METHODS
1 H and 13 C NMR spectra were recorded at ambient temperatures at 400 and 100 MHz, respectively, using a Bruker Avance-400 NMR spectrometer, or at 700 and 175 MHz, respectively, using Bruker Avance-700 NMR spectrometer. The chemical shifts are reported in ppm units ( ) relative to TMS at 0 ppm. The residual hydrogen signals of the deuterated solvents ( H = 7.26 ppm in CDCl 3 , 7.16 ppm in C 6 D 6 , and 2.50 ppm in DMSO-d 6 ) were used as internal references in the 1 H NMR measurements [22] . In the 13 C NMR measurements, the chemical shifts were referenced to the signals of CDCl 3 ( C = 77.1 ppm), C 6 D 6 (128.0 ppm) and DMSO-d 6 (39.5 ppm) [22] . Coupling constants, J, are reported in Hertz. All the given assignments are based on a combination of 1D ( 1 H and 13 C/DEPT) and 2D (COSY, HMQC, and HMBC) NMR spectra. The splitting pattern and the assignment abbreviations are as follows: s, singlet; d, doublet; t, triplet; q, quartet; qui, quintet; m, unresolved multiplet; br., broad; BZM, benzimidazole; and Th, thiophene.
High-resolution mass spectra (HRMS) were obtained using a QTOF instrument (Agilent) or an LTQ Orbitrap XL (Thermo Scientific) mass spectrometer in electrospray ionization (ESI) mode. The specific light rotation was measured with a JASCO digital polarimeter (Model P-1010 = 589 nm, ±0.05° accuracy) using a cylindrical quartz cell (5 mL, L = 5 cm) at room temperature by dissolving the crystals in Dry THF was prepared by refluxing over sodium/benzophenone ketyl, followed by distillation under nitrogen. Other commercially available reagents and solvents were purchased and used as received.
EXPERIMENTAL

Synthetic Procedures
Methyl 4-fluoro-3-nitrobenzoate (2) [12]
4-Fluoro-3-nitrobenzoic acid (5.55 g, 29.98 mmol) was dissolved in methanol (50 mL) and concentrated H 2 SO 4 (6.40 mL) was added. The reaction mixture was refluxed for 3 h with protection from atmospheric moisture. The reaction mixture was cooled to ambient temperature and poured into crushed ice. The precipitated colorless solid was collected by suction, thoroughly washed with water, and dried in vacuum to afford 5.49 g (91%) of the NMR-pure ester 2. 1 H, 13 C/DEPT NMR spectra, and m.p. of the prepared 2 completely match the reported data [12] .
Methyl 3-nitro-4-(pentan-3-ylamino)benzoate (3)
To a mixture of methyl 4-fluoro-3-nitrobenzoate (2) (5.0 g, 25.3 mmol) and K 2 CO 3 (5.2 g, 38.0 mmol) in dry THF (25.0 mL) under nitrogen, 3-aminopentane (3.3 mL, 2.5 g, 28.6 mmol) was added. After 4 h stirring at room temperature, THF was removed under reduced pressure, and water (100 mL) was added to the residue. The aqueous phase was extracted with ethyl acetate (3 x 100 mL). The combined organic phases were followed by washing with additional water (150 mL), drying over sodium sulfate, filtering and evaporating to yield 6.17 g (92%) of the NMR-pure product 3 as an orange oil. 1 
Methyl 3-amino-4-(pentan-3-ylamino)benzoate (4)
A solution of methyl 3-nitro-4-(pentan-3-ylamino)benzoate (3) (6.2 g, 23.2 mmol) in ethanol (70 mL) was hydrogenated with molecular hydrogen at 5 bar over 10% Pd/C (0.35 g, 0.33 mmol Pd) for 16 h in a Parr machine. The reaction mixture was filtered via a plug of Celite, and ethanol was removed under reduced pressure to yield an oily residue. Purification of the residue by FC on silica gel (20% ethyl acetate in hexane) afforded 4.7 g (85%) of the title product as a brownish waxy solid, R f = 0.22 (ethyl acetate/hexane, 1:4). 1 
Methyl 2-(thiophen-2-yl)acetimidate Hydrochloride (6)
Acetyl chloride (8.0 mL, 8.8 g, 101.3 mmol) was added dropwise over 10 min to a cold (0 °C) well-stirred solution of 2-thiopheneacetonitrile (5) (3.4 mL, 4.0 g, 32.4 mmol) and dry methanol (6.6 mL, 5.2 g, 162.9 mmol) in dry diethyl ether (30 mL) under nitrogen. After the addition, the reaction mixture was stirred at 0 °C for an additional hour, then was closed well and kept in the cold (4 °C) without stirring. Colorless crystals precipitated after 3 days. The crystals were filtered via a glass sinter, washed with dry ether (60 mL), and then dried in vacuum to generate 5.44 g (87%) of a highly hydroscopic solid imidate salt 6. 1 Methyl 1-(pentan-3-yl)-2-(thiophen-2-ylmethyl) 
4.1.5.
-1Hbenzo[d]imidazole-5-carboxylate (7)
A homogeneous solution of methyl 3-amino-4-(pentan-3ylamino)benzoate (4) (3.0 g, 12.9 mmol) and methyl 2thiopheneacetimidate hydrochloride (6) (2.5 g, 12.9 mmol) was refluxed in dry methanol (20.0 mL) for 8 h under nitrogen. The methanol was removed under reduced pressure, the residue was partitioned between ethyl acetate (200 mL) and water (100 mL), the organic layer was washed with additional water (2x100 mL) and brine (100 mL), and dried over sodium sulfate. Filtration, then evaporation followed by FC on silica gel (gradient elution with ethyl acetate -hexane) yielded 2.5 g (57%) of the title product 7, R f = 0.45 (ethyl acetate -toluene, 3:7). A beige solid, m.p. 101-103 °C. 1 13 4.1.6. 1-(Pentan-3-yl)-2-(thiophen-2-ylmethyl)-1H-benzo[d] 
imidazole-5-carboxylic Acid (8)
To a solution of methyl ester 7 (200 mg, 0.6 mmol) in methanol (2.0 mL) and THF (3.0 mL), 1 M aqueous solution of sodium hydroxide (1.2 mL) was added, and the reaction mixture was stirred at room temperature overnight. The solvents were removed under reduced pressure and water (50 mL) was added. The mixture was adjusted to pH 4 by the addition of 2.0 M aqueous HCl and the aqueous phase was extracted with ethyl acetate (3 x 100 mL). The combined organic phase was followed by washing with brine (100 mL), drying over sodium sulfate, filtering, evaporating, and vacuuming to afford 170 mg (87%) of carboxylic acid 8 as a light brown solid, mp 83-86 °C. 1 
Methyl (S)-5-methyl-3-{(1-(pentan-3-yl)-2-(thiophen-2-ylmethyl)-1H-benzo[d]imidazole-5-carboxamido)}hexanoate (9)
To a well-stirred solution of carboxylic acid 8 (500 mg, 1.5 mmol) in dry DMF (10 mL) at 0 °C under nitrogen, HOBt (310 mg, 2.3 mmol), EDC (450 mg, 2.89 mmol), and DIEA (0.60 mL, 452 mg, 3.9 mmol) were added consecutively. After 15 min stirring at 0 °C, a solution of methyl (S)-3-amino-5methylhexanoate (850 mg, 5.3 mmol) and DIEA (0.6 mL, 452 mg, 3.9 mmol) in dry DMF (2 mL) was added. The reaction mixture was stirred at ambient temperature for 3 days and poured into water (125 mL). The solution was acidified to pH 13 
Potassium (S)-5-methyl-3-{1-(pentan-3-yl)-2-(thiophen-2-ylmethyl)-1H-benzo[d]imidazole-5-carboxamido} hexanoate -CMF-019 (potassium salt) (10)
To a solution of methyl ester 9 (50 mg, 0.1 mmol) in THF (1.0 mL) an aqueous solution of KOH (7 mg, 0.12 mmol in 0.6 mL of H 2 O) was added slowly at 0 °C and the reaction mixture was stirred at room temperature for 21 h. THF and water were removed under reduced pressure to afford an oily residue. The residue was treated with ethyl ether (10 mL), and the mixture was stirred for 30 min to afford a pale insoluble precipitate. The solution was decanted off the solid and discarded. The solid residue was purified using reverse phase preparative HPLC to afford, after thorough lyophilization for 5 days, 30 mg (57%) of the target CMF-019 (potassium salt) (10). The product is a colorless hydroscopic powder, m.p. 116-120 °C; [ ] D 25 = 16.9 (c = 0.002, CHCl 3 ). 1 13 
CONCLUSION
An improved, convenient synthesis of CMF-019 (potassium salt) (10) was developed and reported here with detailed synthetic procedures and spectroscopic data. The elaborated synthesis avoids the use of high-pressure hydrogenation and a dedicated microwave reactor. Since 10 is a potent APJ receptor agonist, a description of its expedient synthesis could benefit investigating the apelin-APJ system and potential treatment of the system's dysfunctionassociated disorders.
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